TapewireFind a company

person · Reporting owner

Wettig Thane

Disclosed activity across 1 company

Tapewire entity
40237
SEC CIK
0001815638

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
KYNTRA BIO, INC.KYNB · Entity 7431Director · CEOSeptember 06, 2026September 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

KYNTRA BIO, INC.

Report date September 06, 2026 · Filed September 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect26,796 Reported balance After 2026-09-06 transaction · row 1
1 source row

Row 1 · 2026-09-06 · Tax withholding · Disposed 209 · Balance 26,796

F1: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units

Common StockSEC Table I · non-derivativeIndirectBy spouse40 Reported balance Holding disclosure · report date 2026-09-06 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 40

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 06, 2026 Filed Sep 10, 2026 00:42 UTC KYNTRA BIO, INC. KYNB · Entity 7431 Tax withholdingCommon Stock 209 $8.55 $1,786.95
Disclosure

SEC source: 0001815638-26-000011 · form4-09102026_120924.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,796

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units

Read SEC document
June 06, 2026 Filed Jun 9, 2026 21:46 UTC KYNTRA BIO, INC. KYNB · Entity 7431 Tax withholdingCommon Stock 198 $6.71 $1,328.58
Disclosure

SEC source: 0001815638-26-000009 · form4-06092026_090658.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,005

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
May 14, 2026 Filed May 18, 2026 12:00 UTC KYNTRA BIO, INC. KYNB · Entity 7431 PurchaseCommon Stock 2,800 $7.09 $19,852.00
Disclosure

SEC source: 0001815638-26-000005 · form4-05182026_080501.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,203

Read SEC document
May 14, 2026 Filed May 19, 2026 19:08 UTC Amendment KYNTRA BIO, INC. KYNB · Entity 7431 PurchaseCommon Stock 2,800 $7.09 $19,852.00
Disclosure

SEC source: 0001815638-26-000007 · form4a-05192026_070512.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,203

Read SEC document
March 06, 2026 Filed Mar 10, 2026 21:41 UTC KYNTRA BIO, INC. KYNB · Entity 7431 Tax withholdingCommon Stock 277 $6.84 $1,894.68
Disclosure

SEC source: 0001815638-26-000003 · form4-03102026_090328.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,403

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
February 03, 2026 Filed Feb 6, 2026 02:08 UTC KYNTRA BIO, INC. KYNB · Entity 7431 GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0001815638-26-000002 · form4-02062026_020215.xml · derivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-02-02

F1 · derivative.exercise_date: The option vests in equal amount quarterly over 4 years measured from 2/3/2026.

Read SEC document
December 06, 2025 Filed Dec 9, 2025 21:10 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 259 $8.42 $2,180.78
Disclosure

SEC source: 0001815638-25-000005 · form4-12092025_091206.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,680

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
November 17, 2025 Filed Nov 17, 2025 21:42 UTC KYNTRA BIO, INC. FGEN · Entity 7431 PurchaseCommon Stock 2,700 $9.10 $24,569.73
Disclosure

SEC source: 0001815638-25-000004 · form4-11172025_091148.xml · nonDerivative · entry 2

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,939

Read SEC document
November 13, 2025 Filed Nov 17, 2025 21:42 UTC KYNTRA BIO, INC. FGEN · Entity 7431 PurchaseCommon Stock 1,000 $9.18 $9,180.00
Disclosure

SEC source: 0001815638-25-000004 · form4-11172025_091148.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,239

Read SEC document
September 06, 2025 Filed Sep 9, 2025 23:25 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 248 $12.10 $3,000.80
Disclosure

SEC source: 0001415889-25-024012 · form4-09092025_110909.xml · nonDerivative · entry 2

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,239

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
June 06, 2025 Filed Sep 9, 2025 23:25 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 246 $7.83 $1,926.80
Disclosure

SEC source: 0001415889-25-024012 · form4-09092025_110909.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,487

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
March 24, 2025 Filed Mar 25, 2025 13:00 UTC KYNTRA BIO, INC. FGEN · Entity 7431 PurchaseCommon Stock 145,000 $0.35 $50,663.00
Disclosure

SEC source: 0001415889-25-008872 · form4-03252025_090301.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 543,329

F1 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.34 to $0.37. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 06, 2025 Filed Mar 8, 2025 00:03 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 367 $0.39 $143.13
Disclosure

SEC source: 0001415889-25-007459 · form4-03082025_120348.xml · nonDerivative · entry 3

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,329

F3 · shares: Represents the number of shares withheld by the issuer to cover the tax obligation realized upon the vesting of PSU Milestone grant.

Read SEC document
March 06, 2025 Filed Mar 8, 2025 00:03 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 781 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-007459 · form4-03082025_120348.xml · nonDerivative · entry 2

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,696

F2 · shares: Represents the number of shares released for PSU Milestone Grant vested on March 6, 2025.

Read SEC document
March 06, 2025 Filed Mar 8, 2025 00:03 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 22,038 $0.39 $8,594.82
Disclosure

SEC source: 0001415889-25-007459 · form4-03082025_120348.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 397,915

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
January 09, 2025 Filed Jan 10, 2025 23:15 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantStock Option (Right to Buy) · Derivative 1,300,000 $0.00 Strike: $0.65 $0.00
Disclosure

SEC source: 0001415889-25-001310 · form4-01102025_110107.xml · derivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,300,000

Underlying: Common Stock · 1,300,000 shares

Expires 2035-01-08

F1 · derivative.exercise_date: The option vests in equal amount quarterly over 4 years measured from 1/9/2025.

Read SEC document
December 06, 2024 Filed Dec 10, 2024 01:00 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 2,363 $0.34 $808.38
Disclosure

SEC source: 0001415889-24-028743 · form4-12092024_081203.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 419,953

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
September 06, 2024 Filed Sep 10, 2024 00:00 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 2,363 $0.39 $921.57
Disclosure

SEC source: 0001415889-24-023089 · form4-09092024_080904.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 422,316

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
August 01, 2024 Filed Aug 5, 2024 20:18 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 20,840 $0.47 $9,794.80
Disclosure

SEC source: 0001415889-24-020745 · form4-08052024_080844.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 424,679

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
June 22, 2024 Filed Jun 25, 2024 20:30 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 782 $1.13 $883.66
Disclosure

SEC source: 0001415889-24-018145 · form4-06252024_040601.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 445,519

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
June 06, 2024 Filed Jun 7, 2024 23:00 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 2,255 $1.19 $2,683.45
Disclosure

SEC source: 0001415889-24-016079 · form4-06072024_070602.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 446,301

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
May 01, 2024 Filed May 2, 2024 23:46 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 20,840 $1.17 $24,382.80
Disclosure

SEC source: 0001415889-24-012091 · form4-05022024_110520.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 448,556

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
March 22, 2024 Filed Mar 25, 2024 21:58 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 782 $2.58 $2,017.56
Disclosure

SEC source: 0001415889-24-009048 · form4-03252024_090320.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 469,396

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 23:06 UTC KYNTRA BIO, INC. FGEN · Entity 7431 PurchaseCommon Stock 50,000 $1.91 $95,470.00
Disclosure

SEC source: 0001415889-24-007570 · form4-03112024_110334.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 470,178

Read SEC document
March 06, 2024 Filed Mar 9, 2024 00:18 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 326 $1.87 $609.62
Disclosure

SEC source: 0001415889-24-007453 · form4-03092024_120313.xml · nonDerivative · entry 3

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 420,178

F3 · shares: Represents the number of shares withheld by the issuer to cover the tax obligation realized upon the vesting of PSU Milestone grant.

Read SEC document
March 06, 2024 Filed Mar 9, 2024 00:18 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 781 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-007453 · form4-03092024_120313.xml · nonDerivative · entry 2

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 420,504

F2 · shares: Represents the number of shares released for PSU Milestone Grant vested on March 6, 2024.

Read SEC document
March 06, 2024 Filed Mar 9, 2024 00:18 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 4,209 $1.87 $7,870.83
Disclosure

SEC source: 0001415889-24-007453 · form4-03092024_120313.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 419,723

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
February 21, 2024 Filed Feb 24, 2024 01:33 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantStock Option (Right to Buy) · Derivative 834,000 $0.00 Strike: $1.72 $0.00
Disclosure

SEC source: 0001415889-24-005156 · form4-02242024_010232.xml · derivative · entry 3

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 834,000

Underlying: Common Stock · 834,000 shares

Expires 2034-02-20

F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option will vest on March 1, 2025, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years.

Read SEC document
February 21, 2024 Filed Feb 24, 2024 01:33 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 166,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-005156 · form4-02242024_010232.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 423,932

F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2025, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years.

Read SEC document
February 01, 2024 Filed Feb 6, 2024 01:08 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 23,490 $2.37 $55,671.30
Disclosure

SEC source: 0001415889-24-002750 · form4-02062024_010229.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,932

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
December 22, 2023 Filed Dec 27, 2023 00:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 819 $0.76 $622.44
Disclosure

SEC source: 0001209191-23-059713 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,422

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
December 06, 2023 Filed Dec 11, 2023 21:19 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 1,680 $0.58 $974.40
Disclosure

SEC source: 0001209191-23-058051 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,241

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
November 01, 2023 Filed Nov 3, 2023 20:20 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 21,841 $0.55 $11,949.21
Disclosure

SEC source: 0001209191-23-054320 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,921

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
September 22, 2023 Filed Sep 25, 2023 23:37 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 819 $0.79 $643.98
Disclosure

SEC source: 0001209191-23-050526 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,762

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
September 06, 2023 Filed Sep 8, 2023 21:00 UTC KYNTRA BIO, INC. FGEN · Entity 7431 Tax withholdingCommon Stock 1,680 $0.96 $1,618.01
Disclosure

SEC source: 0001209191-23-048815 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Interim CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 306,581

F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 21:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantStock Option (Right to Buy) · Derivative 300,000 $0.00 Strike: $1.77 $0.00
Disclosure

SEC source: 0001209191-23-045215 · doc4.xml · derivative · entry 2

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2033-08-06

F2 · derivative.exercise_date: Twenty-Five percent of the shares subject to the option vest on August 7, 2024 and the remainder vest quarterly in equal installments over the following 3 years, subject to the reporting person's continued service with the company on each such date.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 21:28 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 200,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-045215 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 308,261

F1 · shares: Represents the grant of Restricted Stock Units ("RSUs") that vest quarterly over 1 year from August 1, 2023, subject to the reporting person's continued service with the company on each such date.

Read SEC document
June 23, 2023 Filed Jun 26, 2023 20:27 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 791 $16.53 $13,074.99
Disclosure

SEC source: 0001209191-23-039700 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,261

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:39 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 1,286 $17.04 $21,910.48
Disclosure

SEC source: 0001209191-23-036066 · doc4.xml · nonDerivative · entry 2

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,395

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:39 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 472 $17.04 $8,040.80
Disclosure

SEC source: 0001209191-23-036066 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,681

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

F2 · balance_after: Includes 2,500 shares acquired on May 15, 2023 through the Issuer's Employee Stock Purchase Plan.

Read SEC document
June 07, 2023 Filed Jun 22, 2023 22:32 UTC Amendment KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 1,286 $17.04 $21,910.48
Disclosure

SEC source: 0001209191-23-039157 · doc4a.xml · nonDerivative · entry 2

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,052

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

Read SEC document
June 07, 2023 Filed Jun 22, 2023 22:32 UTC Amendment KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 472 $17.04 $8,040.80
Disclosure

SEC source: 0001209191-23-039157 · doc4a.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,338

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

F2 · balance_after: Includes 2,500 shares acquired on May 15, 2023 through the Issuer's Employee Stock Purchase Plan.

Read SEC document
March 23, 2023 Filed Mar 25, 2023 00:27 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 905 $18.71 $16,932.55
Disclosure

SEC source: 0001209191-23-021138 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,653

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

Read SEC document
March 20, 2023 Filed Mar 29, 2023 21:05 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GiftCommon Stock 1,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-021539 · doc4.xml · nonDerivative · entry 2

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 1,000

F1 · balance_after: The share total in column 5 reflects ownership as of March 28, 2023.

Read SEC document
March 20, 2023 Filed Mar 29, 2023 21:05 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GiftCommon Stock 2,343 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-021539 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,310

F1 · balance_after: The share total in column 5 reflects ownership as of March 28, 2023.

Read SEC document
March 10, 2023 Filed Mar 11, 2023 02:53 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 4,731 $20.20 $95,553.43
Disclosure

SEC source: 0001209191-23-018061 · doc4.xml · nonDerivative · entry 5

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,558

F4 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of PSU TSR previously reported in Table I.

Read SEC document
March 10, 2023 Filed Mar 11, 2023 02:53 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 2,938 $20.20 $59,339.67
Disclosure

SEC source: 0001209191-23-018061 · doc4.xml · nonDerivative · entry 4

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,289

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

Read SEC document
March 08, 2023 Filed Mar 11, 2023 02:53 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCommon Stock 9,338 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-018061 · doc4.xml · nonDerivative · entry 3

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,227

F3 · shares: Represents the number of shares released for PSU TSR Grant vested on March 8, 2023.

Read SEC document
March 08, 2023 Filed Mar 11, 2023 02:53 UTC KYNTRA BIO, INC. FGEN · Entity 7431 GrantCOmmon Stock 5,799 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-018061 · doc4.xml · nonDerivative · entry 2

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,889

F2 · shares: Represents the number of shares released for PSU Milestone Grant vested on March 8, 2023.

Read SEC document
March 08, 2023 Filed Mar 11, 2023 02:53 UTC KYNTRA BIO, INC. FGEN · Entity 7431 SaleCommon Stock 6,265 $21.16 $132,541.71
Disclosure

SEC source: 0001209191-23-018061 · doc4.xml · nonDerivative · entry 1

Wettig Thane · CIK 0001815638 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,090

F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.